Novartis' Rhapsido cuts MS relapse rates and shows a clean safety profile in Phase 3 trials; Jefferies sees peak sales above $3B.
September 1, 2026 07:30 AM EDT
R&DPharma
Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
Elizabeth Cairns
Senior biopharma journalist
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both…
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its…
Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the…
Ubs stima una probabilità del 50% di successo per il farmaco sperimentale Remibrutinib con vendite al picco previste a 4,5…
NodThera rebrands to Rezera, plans Phase 3 trial in peripheral artery disease in 2027 with ~800 patients testing NLRP3 inhibitor…
Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors…
